Multicenter, Open-label, Phase IIIb Study to Evaluate the Safety, Tolerability of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Methotrexate or Other Non-biologic Disease-modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis

Trial Profile

Multicenter, Open-label, Phase IIIb Study to Evaluate the Safety, Tolerability of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Methotrexate or Other Non-biologic Disease-modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms TOZURA
  • Sponsors Roche
  • Most Recent Events

    • 06 Apr 2018 Results (n=1804) of pooled data from 11 clinical trials assessing the efficacy, safety and immunogenicity of TCZ-SC 162 mg qw as monotherapy and in combination with csDMARDs over 24 weeks in adult patients with moderate to severe RA in a broad geographic setting, were published in the Rheumatology.
    • 13 Dec 2017 Results (n=1804) of pooled analysis of TOZURA study programme of this and other ten studies assessing efficacy, safety and immunogenecity, published in the Rheumatology.
    • 17 Jun 2017 Results of pooled analysis presented at the 18th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top